These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17153140)

  • 21. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery.
    Johnson MC; Hu Q; Lingardo L; Ferre RA; Greasley S; Yan J; Kath J; Chen P; Ermolieff J; Alton G
    J Comput Aided Mol Des; 2011 Jul; 25(7):689-98. PubMed ID: 21779981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches.
    Mochalkin I; Miller JR; Narasimhan L; Thanabal V; Erdman P; Cox PB; Prasad JV; Lightle S; Huband MD; Stover CK
    ACS Chem Biol; 2009 Jun; 4(6):473-83. PubMed ID: 19413326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.
    Di Lello P; Pastor R; Murray JM; Blake RA; Cohen F; Crawford TD; Drobnick J; Drummond J; Kategaya L; Kleinheinz T; Maurer T; Rougé L; Zhao X; Wertz I; Ndubaku C; Tsui V
    J Med Chem; 2017 Dec; 60(24):10056-10070. PubMed ID: 29166018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits.
    Blaazer AR; Orrling KM; Shanmugham A; Jansen C; Maes L; Edink E; Sterk GJ; Siderius M; England P; Bailey D; de Esch IJ; Leurs R
    J Biomol Screen; 2015 Jan; 20(1):131-40. PubMed ID: 25231971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragments as Novel Starting Points for tRNA-Guanine Transglycosylase Inhibitors Found by Alternative Screening Strategies.
    Hassaan E; Eriksson PO; Geschwindner S; Heine A; Klebe G
    ChemMedChem; 2020 Feb; 15(3):324-337. PubMed ID: 31808981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
    Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
    J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multiple roles of computational chemistry in fragment-based drug design.
    Law R; Barker O; Barker JJ; Hesterkamp T; Godemann R; Andersen O; Fryatt T; Courtney S; Hallett D; Whittaker M
    J Comput Aided Mol Des; 2009 Aug; 23(8):459-73. PubMed ID: 19533374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.
    Mizutani MY; Itai A
    J Med Chem; 2004 Sep; 47(20):4818-28. PubMed ID: 15369385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Library design for fragment based screening.
    Schuffenhauer A; Ruedisser S; Marzinzik AL; Jahnke W; Blommers M; Selzer P; Jacoby E
    Curr Top Med Chem; 2005; 5(8):751-62. PubMed ID: 16101415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of screening collections for successful fragment-based lead discovery.
    Na J; Hu Q
    Methods Mol Biol; 2011; 685():219-40. PubMed ID: 20981526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    de Souza Neto LR; Moreira-Filho JT; Neves BJ; Maidana RLBR; Guimarães ACR; Furnham N; Andrade CH; Silva FP
    Front Chem; 2020; 8():93. PubMed ID: 32133344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular complexity and fragment-based drug discovery: ten years on.
    Leach AR; Hann MM
    Curr Opin Chem Biol; 2011 Aug; 15(4):489-96. PubMed ID: 21665521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.